Two-thirds of patients using weight loss drugs are hiding their treatment from friends and family, according to a 2026 survey. Women are more likely to conceal their use than men.
The investigation, surveying 2,000 UK adults and over 3,000 patients, found over 20% cited fear of social stigma as a primary concern. Nearly 40% of users reported being judged, with many accused of taking "the easy way out" or told to "just eat less and move more." Some described GLP-1 use as cheating or dangerous.
Despite initial judgment, more than half of patients experienced more positive attitudes after losing weight. Researchers suggest public perception lags behind clinical advancements.
Gender differences are notable: nearly 70% of women hid their treatment, compared to just over 50% of men. Women also faced higher rates of judgment. Generation Z showed a particular tendency to conceal treatment, with three-quarters using weight loss drugs in secret.
Regional disparities exist, with England and Scotland reporting the highest levels of stigma around GLP-1 use. Conversely, Wales and Northern Ireland showed lower rates.
Researchers state that concealing treatment hinders open discussion, limits support, and reinforces the idea that medically supervised obesity treatment is illegitimate. This hesitancy in communication can negatively impact treatment adherence and clinical outcomes, potentially increasing the likelihood of weight regain.